A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin or Pembrolizumab in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer

Trial Profile

A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin or Pembrolizumab in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Mirvetuximab soravtansine (Primary) ; Bevacizumab; Carboplatin; Doxorubicin liposomal; Pembrolizumab
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FORWARD II
  • Sponsors ImmunoGen
  • Most Recent Events

    • 03 Nov 2017 According to ImmunoGen media release, updated dose escalation findings from the Phase 1b/2 Keytruda(pembrolizumab) cohort, along with updated data from the Avastin expansion cohort will be reported in the first half of 2018.
    • 03 Nov 2017 According to ImmunoGen media release, a cohort to evaluate the triplet combination of mirvetuximab soravtansine/Avastin (bevacizumab)/carboplatin in patients with platinum sensitive folate receptor alpha (FRa) positive epithelial ovarian cancer will be initiated in 1Q 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top